Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia

Ching Hon Pui, Michael J. Schell, Susana C. Raimondi, David R. Head, Gaston K. Rivera, William M. Crist, Frederick G. Behm, Michael J. Borowitz, Jonathan J. Shuster, Vita J. Land, C. Philip Steuber, D. Jeanette Pullen, Teresa J. Vietti, Hiroyuki Tsuchiya, Norio Asou, Masahiko Watanabe, Akihiro Shimosaka, Kiyoshi Takatsuki, Ichiro Matsuda, Susan R. WiersmaJorge A. Ortega, Eugene Sobel, Kenneth I. Weinberg

Research output: Contribution to journalLetterpeer-review

Abstract

To the Editor: Wiersma and coworkers (March 21 issue)1 found that expression of myeloid antigens (CD14 [My4], CD13 [My7], and CD33 [My9]) was an independent predictor of a poor outcome among 236 children with acute lymphoblastic leukemia (ALL) treated according to at least five different clinical protocols. This result contrasts sharply with our recent observation that myeloid-associated antigens lacked prognostic value in 267 children treated intensively with similar regimens of combination chemotherapy.2 As Wiersma et al. suggest, differences in definitions of myeloid-antigen expression, immunophenotyping methods, study populations, treatment regimens, or a combination of these factors may explain the discordant results.

Original languageEnglish (US)
Pages (from-to)1378-1382
Number of pages5
JournalNew England Journal of Medicine
Volume325
Issue number19
DOIs
StatePublished - Nov 7 1991
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia'. Together they form a unique fingerprint.

Cite this